Bioventus (NASDAQ:BVS) Research Coverage Started at CJS Securities

CJS Securities began coverage on shares of Bioventus (NASDAQ:BVS) in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The firm issued a market outperform rating and a $14.00 target price on the stock.

BVS has been the subject of several other research reports. Barrington Research upped their price target on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Craig Hallum lifted their price objective on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Finally, Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Bioventus currently has a consensus rating of “Buy” and a consensus price target of $14.00.

Bioventus Price Performance

Shares of NASDAQ BVS opened at $8.94 on Friday. The firm has a market cap of $743.36 million, a PE ratio of 27.09 and a beta of 0.78. The firm has a fifty day moving average of $8.49 and a 200 day moving average of $7.67. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. Bioventus has a one year low of $5.81 and a one year high of $9.56.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insiders Place Their Bets

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Anderson Financial Strategies LLC purchased a new stake in shares of Bioventus in the third quarter valued at approximately $901,000. Royce & Associates LP increased its holdings in shares of Bioventus by 15.6% in the third quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock valued at $8,449,000 after purchasing an additional 170,900 shares during the last quarter. American Century Companies Inc. lifted its position in Bioventus by 7.6% during the second quarter. American Century Companies Inc. now owns 1,124,041 shares of the company’s stock worth $7,441,000 after buying an additional 79,829 shares in the last quarter. Geode Capital Management LLC boosted its stake in Bioventus by 13.1% during the second quarter. Geode Capital Management LLC now owns 1,054,903 shares of the company’s stock worth $6,984,000 after buying an additional 122,137 shares during the last quarter. Finally, Prudential Financial Inc. boosted its stake in Bioventus by 182.0% during the second quarter. Prudential Financial Inc. now owns 138,460 shares of the company’s stock worth $917,000 after buying an additional 89,356 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.